LIPIGON PHARMACEUTICALS JOINS ASTRAZENECA'S BIOVENTURHUB
Starting December 2016 Lipigon joins the AZ BioVentureHub located at AstraZeneca's site in Mölndal, Sweden. The contract stretches over 1 year giving Lipigon an office and full access to the whole facility, including infrastructure and capabilities.
LIPIGON WELCOMES NEW INVESTORS AND PARTNERS
Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.
LIPIGON PHARMACEUTICALS AND ASTRAZENECA ENTER DRUG DISCOVERY COLLABORATION
Lipigon Pharmaceuticals today announced that it has entered into a research collaboration with AstraZeneca to conduct joint research to identify drug candidates that promote the stabilization of Lipoprotein Lipase (LPL) and may have utility in the treatment of lipid disorders and cardiovascular disease.
LIPIGON SIGNS DEAL WITH ASTRAZENECA
UMEÅ, November 18th. Lipigon Pharmaceuticals and AstraZeneca enter research collaboration to develop a high throughput assay for the identification of molecules that modulate lipoprotein lipase activity
Lipigon Pharmaceuticals AB
Webbplats:
www.lipigon.se
Bransch: Sjukvård
Kortnamn: LPGO
Marknadsplats: Nasdaq First North Growth Market
Nästa evenemang:
2022-08-30 Delårsrapport Q2 2022
Kurs
Kurs:
Marknadsvärde: